Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler

• Published in: Diabetes & vascular disease research 2007-12, Vol.4 (4), p.358-364
• Main Authors: Siegmund, Thorsten, Schumm-Draeger, Petra-Maria, Antoni, Diethmar, Von Bibra, Helene
• Format: Article
• Language: English
• Subjects: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diastole - drug effects; Echocardiography, Doppler; Female; Hemodynamics - drug effects; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Ramipril - therapeutic use; Systole - drug effects; Ventricular Function - drug effects; Ventricular Function - physiology
• ISSN: 1479-1641; 1752-8984
• DOI: 10.3132/dvdr.2007.065

Angiotensin-converting enzyme (ACE) inhibitors can improve cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM). Myocardial diastolic function (Ve) is a known marker of cardiovascular prognosis. It could potentially indicate the effects of preventive therapy if evaluated by tissue Doppler. We tested the hypothesis that treatment with the ACE inhibitor ramipril has beneficial effects on Ve. In this study, 16 subjects on insulin therapy (eight receiving 10 mg ramipril/day compared to eight matched controls who were not treated with an ACE inhibitor) were followed up for a period of nine months. Myocardial and vascular function were assessed by tissue Doppler and ultrasound. In the ramipril group, Ve improved significantly after nine months of treatment (7.8±0.9 cm/s to 8.6±0.9 cm/s, p